recent
studi
shown
interferongamma
ifng
synerg
ifnah
inhibit
replic
rna
dna
virus
investig
effect
ifn
replic
two
strain
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
treatment
vero
cell
uml
either
ifnh
ifng
margin
reduc
viral
replic
treatment
ifnh
ifng
inhibit
sarscov
plaqu
format
replic
h
n
fold
h
postinfect
studi
suggest
combin
ifn
treatment
warrant
investig
treatment
sar
sever
acut
respiratori
syndrom
sar
newli
recogn
ill
spread
southern
china
late
sever
countri
asia
europ
north
america
sar
usual
begin
fever
greater
initi
symptom
also
includ
headach
malais
mild
respiratori
symptom
within
day
week
sar
patient
may
develop
dri
cough
troubl
breath
patient
advanc
stage
sar
develop
either
pneumonia
respiratori
distress
syndrom
initi
outbreak
case
worldwid
overal
mortal
http
wwwwhointcsrsarsen
previous
unrecogn
coronaviru
cov
demonstr
caus
new
diseas
drosten
et
al
ksiazek
et
al
peiri
et
al
remark
short
period
time
entir
genet
sequenc
sever
strain
novel
sarscov
determin
virion
receptor
identifi
similar
cov
isol
civet
anim
trap
food
medicin
live
anim
market
guangdong
provinc
china
presum
epicent
outbreak
sarscov
close
relat
cov
also
infect
anim
wild
appear
enter
human
popul
past
zheng
et
al
current
strategi
treatment
sar
patient
includ
broadspectrum
antibiot
glucocorticoid
ribavirin
fujii
et
al
howev
efficaci
treatment
still
unclear
therefor
develop
better
treatment
strategi
futur
outbreak
imper
understand
relationship
see
front
matter
elsevi
inc
right
reserv
viru
host
immun
system
type
ifn
ifna
ifnh
type
ii
ifn
ifng
import
compon
host
immun
respons
viral
infect
ifna
ifnh
produc
cell
direct
respons
viral
infect
ifng
synthes
almost
exclus
activ
natur
killer
nk
cell
activ
cell
respons
virusinfect
cell
pfeffer
et
al
type
ifn
achiev
antivir
effect
induc
synthesi
sever
protein
interfer
viral
replic
goodbourn
et
al
sever
studi
examin
antivir
effect
ifn
sarscov
although
result
clinic
studi
use
ifna
inconclus
haagman
et
al
loutfi
et
al
vitro
studi
strongli
suggest
ifnh
concentr
greater
uml
margin
inhibit
replic
sarscov
hensley
et
al
spiegel
et
al
stroher
et
al
likewis
analysi
cytokin
level
sar
patient
suggest
presenc
ifng
earli
stage
diseas
onset
correl
resolut
viral
infect
kelvin
cameron
person
commun
howev
ifng
littl
antivir
effect
sarscov
vitro
spiegel
et
al
recent
studi
examin
antivir
effect
ifn
rna
dna
virus
shown
use
combin
ifng
synerg
innat
ifn
ifna
ifnh
inhibit
replic
virus
herp
simplex
viru
sainz
halford
hepat
c
viru
larkin
et
al
lassa
viru
asper
et
al
cytomegaloviru
sainz
et
al
unpublish
data
test
principl
examin
antivir
effect
recombin
ifnh
andor
ifng
sarscov
replic
vitro
capac
human
ifnh
andor
ifng
inhibit
replic
sarscov
strain
urbani
initi
compar
plaqu
reduct
assay
vero
cell
cultur
pretreat
uml
ifnh
ifng
alon
sarscov
form
averag
plaqu
respect
tabl
level
inhibit
achiev
either
type
type
ii
ifn
treatment
compar
vehicletr
cultur
contrast
level
inhibit
achiev
cultur
pretreat
combin
type
type
ii
ifn
significantli
greater
p
b
cultur
treat
uml
ifnh
ifng
sarscov
plaqu
format
inhibit
yield
averag
approxim
plaqu
level
inhibit
achiev
combin
ifnh
ifng
treatment
consequ
doubl
amount
ifn
per
cultur
increas
concentr
ifn
individu
treat
ifn
group
uml
achiev
similar
inhibitori
effect
tabl
also
test
relev
phenomenon
compar
antivir
effect
ifnh
ifng
treatment
anoth
strain
sarscov
strain
hong
kong
hk
murin
hepat
viru
mhv
strain
unrel
member
coronavirida
famili
consist
result
obtain
urbani
strain
tabl
combin
ifnh
ifng
treatment
inhibit
hk
plaqu
format
greater
data
shown
interestingli
effect
ifn
plaqu
format
significantli
differ
level
inhibit
achiev
either
ifnh
ifng
treatment
alon
approxim
combin
ifnh
ifng
treatment
tabl
ifnh
ifng
inhibit
cov
plaqu
format
f
f
ifnh
ifng
f
vero
cell
treat
vehicl
hu
ifnh
hu
ifng
hu
ifnh
hu
ifng
h
infect
approxim
pfu
sarscov
strain
urbani
cell
receiv
ident
treatment
murin
ifn
infect
approxim
pfu
b
averag
number
plaqu
per
well
dilut
stock
determin
day
postinfect
pi
valu
repres
mean
f
sem
three
independ
experi
c
foldreduct
group
calcul
plaqu
vehicleplaqu
treatment
valu
repres
mean
three
independ
experi
boldfac
type
indic
greater
reduct
viral
plaqu
format
p
b
determin
oneway
anova
tukey
post
hoc
test
comparison
treatment
vehicl
inhibit
plaqu
format
cell
tabl
fig
show
repres
photograph
sarscov
plaqu
format
ifntreat
vero
cell
day
postinfect
pi
consist
experiment
result
summar
tabl
sarscov
plaqu
effici
inhibit
cultur
treat
ifnh
ifng
fig
addit
plaqu
morpholog
vehicl
ifnhor
ifngtreat
cell
averag
mm
size
plaqu
observ
cultur
treat
ifnh
ifng
consist
smaller
averag
v
mm
size
fig
vs
character
inhibitori
effect
ifnh
ifng
treatment
sarscov
replic
threeday
viral
growth
assay
perform
vero
cell
pretreat
h
uml
ifn
separ
combin
infect
sarscov
urbani
hk
strain
moi
pfu
per
cell
cultur
supernat
titer
infecti
viru
h
pi
cultur
treat
uml
ifnh
ifng
urbani
hk
replic
significantli
inhibit
p
b
h
pi
greatest
level
inhibit
observ
ifnh
treat
cultur
fig
fig
hkinfect
cultur
respect
fig
plaqu
reduct
assay
observ
potent
inhibitori
effect
vero
cultur
treat
ifnh
ifng
compar
viral
titer
greater
pfuml
vehicletr
cell
cultur
treat
uml
ifnh
ifng
urbani
replic
titer
pfuml
h
pi
respect
fig
hk
replic
titer
pfuml
h
pi
respect
fig
inhibitori
effect
achiev
combin
ifnh
ifng
treatment
consist
greater
time
point
test
reach
level
greater
fold
h
pi
rel
vehicl
treat
vero
cell
fig
e
contrast
test
combin
ifnh
ifng
treatment
show
increas
antivir
effect
compar
cultur
treat
ifnh
ifng
separ
fig
f
similar
result
obtain
cell
data
shown
although
result
would
suggest
synergist
antivir
effect
observ
cultur
treat
ifnh
ifng
specif
sarscov
exclud
possibl
effect
observ
regard
mhv
plaqu
format
replic
cell
typespecif
degre
cytopath
effect
cpe
cultur
treat
ifn
also
examin
cpe
extens
vehicletr
group
infect
either
urbani
hk
h
pi
fig
e
evid
reduc
number
cell
present
follow
stain
crystal
violet
howev
vari
degre
cpe
observ
ifntreat
cultur
exampl
extent
cpe
observ
ifngtreat
cultur
h
pi
fig
g
consider
less
extent
cpe
observ
ifnhtreat
cultur
h
pi
fig
f
observ
surpris
level
viral
titer
recov
ifnhand
ifngtreat
cultur
h
fig
b
h
data
shown
pi
similar
moreov
compar
vehicletr
individu
ifntreat
cultur
degre
cpe
observ
cell
treat
ifnh
ifng
less
evid
h
pi
monolay
appear
evenli
stain
littl
visibl
cpe
fig
h
observ
consist
level
viral
titer
recov
cultur
h
pi
data
shown
previou
studi
examin
antivir
effect
ifn
sarscov
replic
vitro
antivir
effect
ifn
treatment
vari
base
concentr
type
ifn
studi
examin
antivir
efficaci
ifnh
alon
sarscov
replic
show
level
monolay
inocul
variabl
titer
sarscov
produc
numer
visibl
plaqu
plaqu
number
figur
correspond
quantit
data
present
tabl
cell
stain
neutral
red
day
pi
cultur
photograph
h
later
inhibit
averag
v
concentr
uml
greater
hensley
et
al
spiegel
et
al
likewis
similar
effect
seen
ifna
treatment
stroher
et
al
howev
ifng
shown
ineffect
inhibitor
sarscov
replic
spiegel
et
al
result
present
studi
howev
demonstr
littl
uml
ifnh
ifng
potent
inhibit
sarscov
replic
fold
inhibitori
effect
observ
measur
level
viral
titer
determin
plaqu
assay
describ
materi
method
signific
differ
viral
titer
vero
cell
treat
ifn
rel
cell
treat
vehicl
denot
singl
asterisk
p
b
oneway
anova
tukey
post
hoc
test
df
averag
fold
inhibit
viral
replic
observ
cell
treat
uml
ifnh
ifng
n
ifnh
ifng
calcul
averag
viral
titer
vehicletreatedaverag
viral
titer
ifntreat
oneway
anova
follow
tukey
post
hoc
test
confirm
foldinhibit
sarscov
combin
ifnh
ifng
highli
signific
p
b
time
point
test
viral
plaqu
format
tabl
replic
fig
result
present
herein
indic
effect
far
greater
addit
maintain
h
pi
maximum
length
time
test
effect
two
strain
sarscov
mhv
potent
inhibitori
effect
observ
cultur
treat
ifnh
ifng
synergist
natur
data
would
fit
inequ
synerg
describ
berenbaum
berenbaum
exampl
synergist
relationship
would
exist
level
inhibit
achiev
uml
ifnh
plu
uml
ifng
significantli
greater
level
inhibit
achiev
uml
either
ifnh
ifng
separ
plaqu
reduct
data
present
tabl
support
inequ
suggest
synergist
antivir
relationship
type
type
ii
ifn
regard
sarscov
plaqu
format
likewis
foldinhibit
data
present
fig
strongli
support
hypothesi
ifnh
ifng
synergist
inhibit
replic
sarscov
specif
observ
effect
addit
level
inhibit
viral
replic
predict
cultur
treat
uml
ifnh
ifng
would
equal
sum
level
inhibit
achiev
cultur
treat
uml
ifnh
ifng
separ
urbani
hk
fig
e
level
inhibit
achiev
cultur
treat
uml
ifnh
ifng
approxim
time
greater
sum
foldinhibit
achiev
cultur
treat
uml
ifnh
ifng
separ
extens
synergist
analys
need
conduct
formal
prove
synergi
howev
data
present
herein
strongli
argu
favor
hypothesi
interestingli
degre
cpe
observ
cultur
treat
either
ifnh
ifng
differ
although
level
viral
replic
treatment
group
similar
fig
vs
fig
b
hypothes
differ
cpe
may
reflect
differ
ifn
pathway
use
ifn
respect
may
essenti
factor
consid
mechan
ifnh
ifng
synergist
inhibit
sarscov
replic
type
ifn
ifna
ifnh
type
ii
ifn
ifng
activ
distinct
relat
jakstat
signal
cascad
result
transcript
sever
hundr
ifnstimul
gene
goodbourn
et
al
although
similar
gene
activ
three
ifn
der
et
al
identifi
numer
gene
differenti
regul
ifna
ifnh
ifng
use
oligonucleotid
array
der
et
al
particular
ifnh
stimul
result
identif
twice
mani
gene
compar
ifng
differenti
regul
ifninduc
gene
may
explain
part
synergist
effect
achiev
ifnh
ifng
remain
determin
howev
profil
differ
ifnstimul
gene
present
cell
treat
type
type
ii
ifn
public
health
intervent
surveil
travel
restrict
quarantin
contain
origin
spread
sarscov
appear
stop
spread
sar
appear
new
case
unknown
howev
whether
draconian
contain
measur
sustain
appear
sarscov
human
immun
respons
sarscov
infect
appear
capabl
clear
infect
individu
reduc
sarscov
load
may
possibl
extend
window
time
effect
immun
respons
could
aris
thu
treatment
reduc
sarscov
load
sever
log
infect
individu
could
enabl
individu
control
elimin
surviv
sarscov
infect
combin
ifn
treatment
therefor
warrant
consider
treatment
sar
vero
cell
american
type
cultur
collect
manassa
va
maintain
minimum
essenti
medium
mem
dulbecco
modifi
eagl
medium
dmem
respect
supplement
fetal
bovin
serum
fb
penicillin
g
uml
streptomycin
mgml
mm
lglutamin
co
sarscov
strain
urbani
hong
kong
hereaft
call
hk
propag
vero
cell
mhv
strain
atcc
propag
cell
recombin
human
hu
ifnh
hu
ifng
murin
mu
ifnh
mu
ifng
pbl
biomed
laboratori
new
brunswick
nj
ad
cell
cultur
hs
h
infect
maintain
viral
infect
experi
describ
herein
hu
ifn
use
exclus
vero
cell
mu
ifn
use
treat
cell
addit
concentr
uml
use
experi
unless
state
otherwis
plaqu
reduct
assay
vero
cell
cell
seed
densiti
cell
well
plate
h
later
variou
dose
ifnh
andor
ifng
ad
cultur
medium
h
ifn
treatment
medium
remov
monolay
infect
fix
inoculum
sarscov
strain
urbani
hk
h
adsorpt
inoculum
remov
cell
wash
twice
phosphat
buffer
salin
overlaid
fbsdmem
contain
seaplaqu
agaros
cambrex
bio
scienc
rockland
inc
rockland
ifn
type
concentr
use
pretreat
cell
stain
neutral
red
day
pi
mhv
day
pi
sarscov
plaqu
number
determin
h
later
viru
replic
assay
vero
cell
cell
seed
densiti
cell
well
plate
h
later
uml
ifnh
andor
ifng
ad
cultur
medium
h
ifn
treatment
cell
monolay
inocul
sarscov
strain
urbani
hk
multipl
infect
moi
pfu
per
cell
h
adsorpt
inoculum
remov
monolay
wash
twice
phosphat
buffer
salin
fresh
ifncontain
cultur
medium
return
well
twentyfour
h
pi
titer
infecti
viru
cell
supernat
determin
serial
dilut
plaqu
assay
vero
cell
sarscov
cell
mhv
data
present
mean
f
standard
error
mean
sem
data
ifntreat
group
compar
vehicletr
group
signific
differ
determin
oneway
analysi
varianc
anova
follow
tukey
post
hoc
test
graphpad
prism
home
san
diego
ca
